VIP

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide and neuromodulator produced throughout the central and peripheral nervous system. It is found in high concentrations in the gut, pancreas, lungs, and hypothalamus (specifically the suprachiasmatic nucleus, the brain's master circadian clock). VIP belongs to the glucagon superfamily of peptides and shares structural similarities with secretin, glucagon, and pituitary adenylate cyclase-activating peptide (PACAP). Despite the 'vasoactive' designation from its early characterization as a vasodilator, VIP's biological roles extend far beyond vascular tone, encompassing inflammation regulation, immune modulation, circadian rhythm synchronization, neuroprotection, and gastrointestinal secretion.

VIP exerts its effects primarily through two G-protein-coupled receptor subtypes: VPAC1 (widely distributed across immune cells, lungs, liver, and intestine) and VPAC2 (predominant in smooth muscle, heart, and thymus). Both receptors couple to Gs proteins, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream transcription factors including CREB, ultimately regulating gene expression for anti-inflammatory mediators. The result is smooth muscle relaxation, vasodilation, and a coordinated shift in immune cell behavior away from pro-inflammatory phenotypes and toward tolerogenic, anti-inflammatory states.

The immunomodulatory profile of VIP is one of its most clinically significant properties. VIP actively suppresses the production of pro-inflammatory cytokines including TNF-alpha, IL-1, IL-6, IL-12, and IFN-gamma from activated macrophages and T cells, while simultaneously upregulating anti-inflammatory mediators including IL-10, IL-1 receptor antagonist, and TGF-beta. VIP also inhibits macrophage activation and promotes the differentiation of regulatory T cells (Tregs) over pro-inflammatory Th1 and Th17 phenotypes. This shift in cytokine balance has made VIP a subject of intense interest in autoimmune and inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, and septic shock.

In the clinical arena, VIP has gained attention through two specific applications. First, Ritchie Shoemaker's Chronic Inflammatory Response Syndrome (CIRS) protocol incorporates VIP nasal spray as a final-stage intervention after other biomarkers have been normalized, targeting persistent neuroinflammatory symptoms in patients exposed to water-damaged building environments. Second, aviptadil (a synthetic VIP formulation) received FDA Fast Track designation for Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, based on VIP's known protective effects in pulmonary vascular smooth muscle and its anti-cytokine activity.